Tavexia Lifecare Board Meeting Oct 7 to Discuss Meyonex Acquisition

Tavexia Lifecare Ltd has scheduled a Board of Directors meeting for October 7, 2026, to further discuss and approve the proposed acquisition of up to 60% equity share capital in Meyonex Pharmaceuticals Limited. This follows a previous board approval on September 7, 2026, which authorized preliminary due diligence and negotiations. The meeting will also address the trading window closure for designated persons and their relatives, effective from September 30, 2026, until 48 hours after the board meeting for un-audited financial results.